Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: PROSTATIC NEOPLASMS - BLOOD , . Treffer: 29
2017
Ebai, T; Souza de Oliveira, FM; Löf, L; Wik, L; Schweiger, C; Larsson, A; Keilholtz, U; Haybaeck, J; Landegren, U; Kamali-Moghaddam, M
Analytically Sensitive Protein Detection in Microtiter Plates by Proximity Ligation with Rolling Circle Amplification.
Clin Chem. 2017; 63(9):1497-1505
Doi: 10.1373/clinchem.2017.271833
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Belic, J; Koch, M; Ulz, P; Auer, M; Gerhalter, T; Mohan, S; Fischereder, K; Petru, E; Bauernhofer, T; Geigl, JB; Speicher, MR; Heitzer, E
mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA.
Adv Exp Med Biol. 2016; 924:147-155
Doi: 10.1007/978-3-319-42044-8_28
Web of Science
PubMed
FullText
FullText_MUG
Trummer, O; Langsenlehner, U; Krenn-Pilko, S; Pieber, TR; Obermayer-Pietsch, B; Gerger, A; Renner, W; Langsenlehner, T
Vitamin D and prostate cancer prognosis: a Mendelian randomization study.
World J Urol. 2016; 34(4):607-611
Doi: 10.1007/s00345-015-1646-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Ulz, P; Belic, J; Graf, R; Auer, M; Lafer, I; Fischereder, K; Webersinke, G; Pummer, K; Augustin, H; Pichler, M; Hoefler, G; Bauernhofer, T; Geigl, JB; Heitzer, E; Speicher, MR
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.
Nat Commun. 2016; 7(15):12008-12008
Doi: 10.1038/ncomms12008
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2015
Belic, J; Koch, M; Ulz, P; Auer, M; Gerhalter, T; Mohan, S; Fischereder, K; Petru, E; Bauernhofer, T; Geigl, JB; Speicher, MR; Heitzer, E
Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach.
Clin Chem. 2015; 61(6):838-849
Doi: 10.1373/clinchem.2014.234286
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Thurner, EM; Krenn-Pilko, S; Langsenlehner, U; Stojakovic, T; Pichler, M; Gerger, A; Kapp, KS; Langsenlehner, T
The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients.
World J Urol. 2015; 33(10):1467-1473
Doi: 10.1007/s00345-014-1459-2
Web of Science
PubMed
FullText
FullText_MUG
Thurner, EM; Krenn-Pilko, S; Langsenlehner, U; Stojakovic, T; Pichler, M; Gerger, A; Kapp, KS; Langsenlehner, T
The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
Eur J Cancer. 2015; 51(5):610-619
Doi: 10.1016/j.ejca.2015.01.002
Web of Science
PubMed
FullText
FullText_MUG
2014
Rieken, M; Kluth, LA; Xylinas, E; Fajkovic, H; Becker, A; Karakiewicz, PI; Herman, M; Lotan, Y; Seitz, C; Schramek, P; Remzi, M; Loidl, W; Pummer, K; Lee, RK; Faison, T; Scherr, DS; Kautzky-Willer, A; Bachmann, A; Tewari, A; Shariat, SF
Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer.
World J Urol. 2014; 32(4):999-1005
Doi: 10.1007/s00345-013-1171-7
Web of Science
PubMed
FullText
FullText_MUG
Todenhöfer, T; Hennenlotter, J; Leidenberger, P; Wald, A; Hohneder, A; Kühs, U; Mischinger, J; Aufderklamm, S; Gakis, G; Blumenstock, G; Stenzl, A; Schwentner, C
Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
BJU Int. 2014; 113(1):152-159
Doi: 10.1111/j.1464-410X.2012.11759.x
Web of Science
PubMed
FullText
FullText_MUG
2012
Todenhöfer, T; Hennenlotter, J; Feyerabend, S; Aufderklamm, S; Mischinger, J; Kühs, U; Gerber, V; Fetisch, J; Schilling, D; Hauch, S; Stenzl, A; Schwentner, C
Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.
Anticancer Res. 2012; 32(8):3507-3513
Web of Science
PubMed
2011
Shariat, SF; Chromecki, TF; Hoefer, J; Barbieri, CE; Scherr, DS; Karakiewicz, PI; Roehrborn, CG; Montorsi, F; Culig, Z; Cavarretta, IT
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.
J Urol. 2011; 186(5):2107-2114
Doi: 10.1016/j.juro.2011.06.048
Web of Science
PubMed
FullText
FullText_MUG
2010
Augustin, H; Isbarn, H; Auprich, M; Bonstingl, D; Al-Ali, BM; Mannweiler, S; Pummer, K
Head to head comparison of three generations of Partin tables to predict final pathological stage in clinically localised prostate cancer.
Eur J Cancer. 2010; 46(12): 2235-2241.
Doi: 10.1016/j.ejca.2010.04.013
Web of Science
PubMed
FullText
FullText_MUG
Augustin, H; Sun, M; Isbarn, H; Pummer, K; Karakiewicz, P
Decision curve analysis to compare 3 versions of Partin Tables to predict final pathologic stage.
Urol Oncol. 2010; 30(4):396-401
Doi: 10.1016/j.urolonc.2010.07.003
Web of Science
PubMed
FullText
FullText_MUG
Fuchsjager, MH; Pucar, D; Zelefsky, MJ; Zhang, ZG; Mo, QX; Ben-Porat, LS; Shukla-Dave, A; Wang, LA; Reuter, VE; Hricak, H
PREDICTING POST-EXTERNAL BEAM RADIATION THERAPY PSA RELAPSE OF PROSTATE CANCER USING PRETREATMENT MRI
INT J RADIAT ONCOL. 2010; 78(3): 743-750.
Doi: 10.1016/j.ijrobp.2009.08.040
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2009
Fuchsjager, MH; Shukla-Dave, A; Hricak, H; Wang, L; Touijer, K; Donohue, JF; Eastham, JA; Kattan, MW
Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy
BJU INT. 2009; 104(3): 315-320.
Doi: 10.1111/j.1464-410X.2009.08406.x
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2008
Langsenlehner, T; Langsenlehner, U; Renner, W; Krippl, P; Mayer, R; Wascher, TC; Kapp, KS
Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer.
Eur J Cancer. 2008; 44(11):1572-1576
Doi: 10.1016/j.ejca.2008.04.021
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2007
Briganti, A; Chun, FK; Hutterer, GC; Gallina, A; Shariat, SF; Salonia, A; Scattoni, V; Valiquette, L; Montorsi, F; Rigatti, P; Graefen, M; Huland, H; Karakiewicz, PI
Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy.
Eur Urol. 2007; 52(3):733-743
Doi: 10.1016/j.eururo.2007.02.054
Web of Science
PubMed
FullText
FullText_MUG
Chun, FK; Hutterer, GC; Perrotte, P; Gallina, A; Valiquette, L; Benard, F; McCormack, M; Briganti, A; Ionescu, C; Jeldres, C; Guay, JP; Saad, F; Karakiewicz, PI
Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
BJU Int. 2007; 100(1):37-41
Doi: 10.1111/j.1464-410X.2007.06923.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Chun, FKH; Briganti, A; Gallina, A; Hutterer, GC; Shariat, SF; Antebie, E; Walz, J; Roehrborn, CG; Salonia, A; Rigatti, P; Saad, F; Huland, H; Montotsi, F; Graefen, M; Karakiewicz, PI
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Eur Urol. 2007; 52(4):1067-1074
Doi: 10.1016/j.eururo.2007.03.018
Web of Science
PubMed
FullText
FullText_MUG
Hutterer, G; Perrotte, P; Gallina, A; Walz, J; Jeldres, C; Traumann, M; Suardi, N; Saad, F; Bénard, F; Valiquette, L; McCormack, M; Graefen, M; Montorsi, F; Karakiewicz, PI
Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening.
Eur J Cancer. 2007; 43(7):1180-1187
Doi: 10.1016/j.ejca.2007.01.005
Web of Science
PubMed
FullText
FullText_MUG
2006
Augustin, H; Auprich, M; Stummvoll, P; Lipsky, K; Pummer, K; Petritsch, P
Shift of tumor features in patients with clinically localized prostate cancer undergoing radical prostatectomy since the beginning of the PSA era.
Wien Klin Wochenschr. 2006; 118(11-12):348-354
Doi: 10.1007/s00508-006-0608-z
Web of Science
PubMed
FullText
FullText_MUG
2004
Augustin, H; Erbersdobler, A; Hammerer, PG; Graefen, M; Huland, H
Prostate cancers in the transition zone: Part 2; clinical aspects.
BJU Int. 2004; 94(9):1226-1229
Doi: 10.1111/j.1464-410X.2004.05147.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2003
Augustin, H; Erbersdobler, A; Graefen, M; Fernandez, S; Palisaar, J; Huland, H; Hammerer, P
Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones.
PROSTATE. 2003; 55(1): 48-54.
Doi: 10.1002/pros.10216
Web of Science
PubMed
FullText
FullText_MUG
Augustin, H; Erbersdobler, A; Graefen, M; Jaekel, T; Haese, A; Huland, H; Hammerer, PG
Differences in biopsy features between prostate cancers located in the transition and peripheral zone.
BJU INT. 2003; 91(6): 477-481.
Doi: 10.1046/j.1464-410X.2003.04140.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Mayer, R; Pummer, K; Quehenberger, F; Mayer, E; Feigl, G; Langsenlehner, U; Hackl, A
Analysis of competing risk parameters in irradiated prostate cancer patients.
Strahlenther Onkol. 2003; 179(7):452-457
Doi: 10.1007/s00066-003-1058-4
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2002
Mayer, R; Pummer, K; Quehenberger, F; Mayer, E; Fink, L; Hackl, A
Postprostatectomy radiotherapy for high-risk prostate cancer.
Urology. 2002; 59(5):732-739
Doi: 10.1016%2FS0090-4295%2802%2901502-9
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
Vejda, S; Posovszky, C; Zelzer, S; Peter, B; Bayer, E; Gelbmann, D; Schulte-Hermann, R; Gerner, C
Plasma from cancer patients featuring a characteristic protein composition mediates protection against apoptosis.
MOL CELL PROTEOMICS. 2002; 1: 387-393.
Doi: 10.1074/mcp.200004-MCP200
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2000
Djavan, B; Zlotta, A; Remzi, M; Ghawidel, K; Basharkhah, A; Schulman, CC; Marberger, M
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
J Urol. 2000; 163(4):1144-1148
Doi: 10.1016/S0022-5347(05)67711-7
Web of Science
PubMed
FullText
FullText_MUG
1999
Djavan, B; Bursa, B; Seitz, C; Soeregi, G; Remzi, M; Basharkhah, A; Wolfram, R; Marberger, M
Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection.
Urology. 1999; 54(4):603-606
Doi: 10.1016/s0090-4295(99)00280-0
Web of Science
PubMed
FullText
FullText_MUG